Fig. 3
A Relative photon flux of luminescent KLN 205 tumors grafted subcutaneously treated with the respective NPs (100 µg/mouse, single bolus administered peritumorally) or vehicle control expressed as fold-difference compared to the original time point (day 0). B Kaplan-Meyer survival curves of the animals bearing subcutaneous KLN 205 tumors and treated with the respective NPs or vehicle control. C Representative micrographs of hematoxylin and eosin stained tissue sections obtained from different organs of control animals or animals given 33% Cu-doped TiO2 NPs. D Blood biochemistry analysis of blood samples obtained from tumor-bearing DBA2 mice having received saline (control) or 33% Cu-doped TiO2 NPs. E Relative photon flux expressed as fold difference and F Kaplan-Meyer survival curves of DBA2 mice bearing KLN 205 tumors treated with 33% Cu-doped TiO2 NPs, anti-CD8 antibody, combination of both or vehicle control (saline). The anti-CD8 antibody was administered intravenously in 3 different boluses each at 200 µg/mouse at 5, 3 and 1 day prior to NP or PBS administration. G Relative photon flux expressed as fold difference and H Kaplan-Meyer survival curves of DBA2 mice bearing KLN 205 tumors treated with 33% Cu-doped TiO2 NPs, anti-CSF1R antibody, combination of both or vehicle control (saline). The anti-CSFR1 antibody was administered intravenously in 3 different boluses each at 200 µg/mouse at 5, 3 and 1 day prior to NP or PBS administration. I Relative photon flux expressed as fold difference and J Kaplan-Meyer survival curves of DBA2 mice bearing KLN 205 tumors treated with 33% Cu-doped TiO2 NPs, anti-PD1 antibody as immunotherapy, combination of both or vehicle control (saline). The anti-PD1 antibody was administered intravenously in 3 different boluses each at 200 µg/mouse at 2 days prior to, together with or 2 days following NP or PBS administration. Significant differences between a treated group and untreated controls at the same time point are indicated where relevant (p < 0.05: *, p < 0.01: **; p < 0.001: ***; p < 0.0001: ****) based on ANOVA testing using GraphPad Prism 9 (n = 8)